BRAF and melanoma: Although response rates within genetically-selected subpopulations of solid tumor cancer patients can be high, such as 60–80% among BRAFV600E mutant melanoma patients receiving the BRAF inhibitor vemurafenib [1], few patients achieve single-agent complete responses.